Retour à la liste

Clinical experience with BIAsp 30: Results from the Indonesian cohort of the international A1chieve study

Pradana Soewondo, R. Bowo Pramono, Yuanita Asri Langi, Nanny N.M. Soetedjo and Ida Ayu Kshanti

Diabetes Research and Clinical Practice, pages S54 - S59

Published online août-2013


Voir l'article:

Abstract

Aim

To evaluate the safety and effectiveness of biphasic insulin aspart 30 (BIAsp 30) in Indonesian patients with type 2 diabetes (T2D) as part of the 24-week, international, prospective, non-interventional A1chieve study.

Methods

Indonesian patients who started BIAsp 30 were included. Safety and efficacy was measured as part of routine clinical practice at baseline, Week 12 and Week 24. Results: Overall, 1324 patients having a mean±SD age, duration of diabetes and body mass index of 55.2±9.9 yrs, 6.8±5.2 yrs and 24.1±3.6kg/m2, respectively, were enrolled. 67% of patients were insulin-naive and 33% were prior insulin users. Glycaemic control was poor at baseline. After 24 weeks, significant reductions from baseline were observed in the mean glycated haemoglobin A1c (HbA1c) (–2.6%), fasting plasma glucose (–93.8 mg/dL) and postprandial plasma glucose (–134.8 mg/dL) levels in the entire cohort (p < 0.001). Significant reductions were also seen in insulin-naive patients and prior insulin users. At Week 24, 29.9% of patients in the entire cohort achieved target HbA1c level of <7.0%, while 26.7% and 39.2% achieved this target among insulin-naive patients and prior insulin users, respectively. The proportion of patients reporting overall hypoglycaemia significantly decreased in the entire cohort after 24 weeks of BIAsp 30 therapy. A small significant increase in body weight was noted in the entire cohort, insulin-naive patients and prior insulin users.

Conclusion

The current study suggests that BIAsp 30 can be considered as a safe and effective option for initiating as well as intensifying insulin therapy in Indonesian patients with T2D.

Keywords: Type 2 diabetes, Indonesia, Biphasic insulin aspart 30, A1chieve.


Retour à la liste